Sarepta Therapeutics (SRPT) Notes Payables (2014 - 2015)
Sarepta Therapeutics' quarterly Notes Payables came in at $2.5 million in Q4 2015, little changed year-on-year from $2.5 million in Q4 2014, and up 1.59% quarter-over-quarter from $2.5 million in Q3 2015.
Sarepta Therapeutics has reported Notes Payables for 2 years, with the latest figure at $2.5 million in Q4 2015.
- For the quarter ending Q4 2015, Notes Payables changed 0.04% year-over-year to $2.5 million; the trailing twelve-month figure through Dec 2015 stood at $2.5 million (changed 0.04% YoY), and the FY2015 full-year result was $2.5 million, changed 0.04% from the prior year.
- Notes Payables for Q4 2015 stood at $2.5 million, up from $2.5 million in the prior quarter.
- The five-year high for Notes Payables was $4.9 million in Q2 2015, with the low at $2.4 million in Q3 2014.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 2.49 Mn |
| Sep 30, 2015 | 2.45 Mn |
| Jun 30, 2015 | 4.91 Mn |
| Mar 31, 2015 | 4.83 Mn |
| Dec 31, 2014 | 2.49 Mn |
| Sep 30, 2014 | 2.42 Mn |